RSNA In Brief
This article was originally published in The Gray Sheet
Executive Summary
GE/Amersham Health: Firms' research agreement inked Nov. 27 will focus initially on radiopharmaceuticals to be used with positron emission tomography (PET) in diagnosis of Parkinson's disease. FDG and FDOPA are among pharmaceuticals under study. GE Medical Systems also announces FDA approval for its sixteen-slice PET system, to be launched in the U.S. next year...